DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models 2024, Journal of Translational Medicine Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimber...